In the last trading session, 1.27 million Acrivon Therapeutics Inc (NASDAQ:ACRV) shares changed hands as the company’s beta touched 1.58. With the company’s per share price at $1.18 changed hands at $0.03 or 2.61% during last session, the market valuation stood at $37.00M. ACRV’s last price was a discount, traded about -761.02% off its 52-week high of $10.16. The share price had its 52-week low at $1.09, which suggests the last value was 7.63% up since then.
Analysts gave the Acrivon Therapeutics Inc (ACRV) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.22. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ACRV as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Acrivon Therapeutics Inc’s EPS for the current quarter is expected to be -0.58.
Acrivon Therapeutics Inc (NASDAQ:ACRV) trade information
Instantly ACRV was in green as seen at the end of in last trading. With action -1.67%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -80.40%, with the 5-day performance at -1.67% in the red. However, in the 30-day time frame, Acrivon Therapeutics Inc (NASDAQ:ACRV) is -34.81% down.
The consensus price target for the stock as assigned by Wall Street analysts is 20, meaning bulls need an upside of 94.1% from its current market value. According to analyst projections, ACRV’s forecast low is 17 with 30 as the target high. To hit the forecast high, the stock’s price needs a -2442.37% plunge from its current level, while the stock would need to soar -1340.68% for it to hit the projected low.
Acrivon Therapeutics Inc (ACRV) estimates and forecasts
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -74.96%. The 2025 estimates are for Acrivon Therapeutics Inc earnings to increase by 5.79%, but the outlook for the next 5-year period is at 1.64% per year.
Acrivon Therapeutics Inc (NASDAQ:ACRV)’s Major holders
PERCEPTIVE ADVISORS LLC holds the second largest percentage of outstanding shares, with 14.8366% or 5.36 million shares worth $31.09 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF. With 407.49 shares estimated at $0.48 million under it, the former controlled 1.30% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 0.92% of the shares, roughly 287.4 shares worth around $0.34 million.
